Colloidal Bismuth Subcitrate in the Treatment of Helicobacter Pylori Infection

The article deals with the treatment of Helicobater pylori infection. We consider the regimens, which are currently recommended for use and matched the recent data of evidence-based medicine. According to a survey conducted in 2015 in Ukraine, first-line quadruple therapy with the inclusion of bismuth subcitrate showed the effectiveness of more than 90 % in the Eastern and Central regions of the country; the superiority of bismuth-containing regimen over the standard one (89 and 55 % of the successful eradications, respectively) has been also demonstrated. This paper presents the results of research on the effectiveness of first-line anti-Helicobacter pylori therapy consisting of a proton pump inhibitor, clarithromycin, amoxicillin with the addition of colloidal bismuth subcitrate (De Nol) in patients at high risk of developing resistance to clarithromycin. In the group of patients at high risk of resistance to clarithromycin, addition to the standard triple therapy of colloidal bismuth subcitrate has led to an increase in the effectiveness of eradication by 22.1 %, which indicates the feasibility of colloidal bismuth subcitrate (De Nol) inclusion into the treatment regimen for this category of patients